A conference call with CFDA about GCP implementation

2016-06-13 | Beijing

JY Briefly raised industry concerns regarding while doing clinical trials, requirements for clinical trial executive sites, animal tests, country of origin approval, etc.. Mr. Wu gave preliminary advice to those questions. JY also raised proposal to have a roundtable with the Research and Supervision Division. This needs to be further discussed with WU.